Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07559240CT.gov A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants | — | Not Yet Recruiting | — | — | — |
NCT07502001CT.gov Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | — | Not Yet Recruiting | — | — | — |
NCT07521631CT.gov Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | — | Recruiting | — | — | — |
NCT07279194CT.gov Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes | — | Recruiting | — | — | — |
NCT06886126CT.gov Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus | — | Recruiting | — | — | — |
NCT06637020CT.gov Phase Ib Clinical Study of HDM1005 Injection | — | Completed | — | — | — |
NCT06640647CT.gov Phase Ia Clinical Study of HDM1005 Injection | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| hdm1005 (this asset) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | P3 | B · 58 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. hdm1005 in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hdm1005-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →